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Gestational diabetes mellitus (GDM) is a well-characterized disease affecting a significant population of pregnant
women worldwide. It has been widely linked to undue weight gain associated with factors such as diet, obesity,
family history, and ethnicity. Poorly controlled GDM results in maternal and fetal morbidity and mortality. Improved
outcomes therefore rely on early diagnosis and tight glycaemic control. While straightforward protocols exist for
screening and management of diabetes mellitus in the general population, management of GDM remains controversial
with conflicting guidelines and treatment protocols. This review highlights the diagnostic and management options for
GDM in light of recent advances in care.
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Gestational diabetes mellitus (GDM), by definition, is
any degree of glucose intolerance with onset or first rec-
ognition during pregnancy [1, 2]. This definition applies
regardless of whether treatment involves insulin or diet
modification alone; it may also apply to conditions that
persist after pregnancy. GDM affects roughly 7 % of
pregnancies with an incidence of more than 200,000
cases per year [2]. The prevalence, however, varies from
1–14 %, depending on the population and the diagnostic
criteria that have been used [2].
GDM is the most common cause of diabetes during
pregnancy, accounting for up to 90 % of pregnancies
complicated by diabetes [2]. Women with GDM have a
40–60 % chance of developing diabetes mellitus over the
5–10 years after pregnancy [3].
Although GDM has been recognized as a disease for
some time, it remains a controversial entity with conflicting
guidelines and treatment protocols.* Correspondence: ibolinga@gmail.com
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The first screening test for GDM, proposed in 1973,
consisted of the 1-h 50 gm oral glucose tolerance test [4].
While some guidelines recommend universal screening,
others exempt those patients who are categorized as low-
risk. Evidence suggests that universal screening improves
pregnancy outcomes compared to selective screening [5].
However, other researchers argue that screening women
based on their clinical characteristics allows for more effi-
cient selective screening for GDM [6].
Low-risk patients include those women with the fol-
lowing characteristics: <25 years of age; normal body
weight; no first-degree relatives with diabetes; no history
of abnormal glucose metabolism; no history of poor
obstetric outcomes; and not from an ethnic group with a
high diabetes prevalence (Hispanic American, Native
American, Asian American, African American, and Pacific
Islander) [7, 8]. Although some experts recommend
against screening these low-risk patients routinely [2], se-
lective screening could miss approximately 4 % of patients
with GDM [9].
Pregnant women with factors conferring a high risk of
GDM (marked obesity, previous history of GDM, glyco-
suria, or family history of diabetes) should be screened
for GDM as soon as possible, preferably during their
first antenatal visit. If negative, they should be retested
at the beginning of their third trimester between 24 toal. This is an Open Access article distributed under the terms of the Creative
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average risk (neither high nor low risk) should also be
screened between 24 and 28 weeks of gestation [2].
When universal screening is implemented, patients with
no recognized risk factors for GDM also undergo a 1-h
glucose challenge test at 24 to 28 weeks of pregnancy.
The classification criteria are summarized in Table 1 [6].
Fasting plasma glucose and postprandial plasma glucose
have been shown to have low sensitivity as screening tests
for GDM [10, 11], and therefore they are not recom-
mended for screening.
In general, there are two approaches to the evaluation
of women for GDM: the one-step approach and the two-
step approach. In the one-step approach, a diagnostic oral
glucose tolerance test (OGTT) is performed without prior
plasma or serum glucose screening. This approach may be
cost effective in high-risk patients. In the two-step ap-
proach, initial screening involves the glucose challenge
test, which measures the plasma or serum glucose concen-
tration 1 h after a 50-gm oral glucose load. The diagnostic
oral glucose challenge test is performed only in the subset
of women found to have plasma or serum glucose concen-
tration values exceeding the threshold for the glucose
challenge test.
When the threshold for glucose challenge test is
>140 mg/dl (7.8 mmol/l), the sensitivity is 80 %; when
it is 130 mg/dl (7.2 mmol/l), the sensitivity becomes
90 % [1]. Whichever approach is used, the diagnosis of
GDM is established only after performing an OGTT.
Diagnostic criteria
There are two major diagnostic criteria for the 3-h 100-gm





High risk • Marked obesity
• Diabetes in first degree relative
• Current glycosuria
• Previous history of GDM or glucose intolerance
• Previous poor obstetric outcome (e.g. an infant with
marosomia)
Average risk • Neither high nor low risk
Low risk • Age <25 years
• No history of poor obstetric outcomes
• Belongs to low risk ethnic groups (ethnic groups other
than Hispanic, African American, Native American, South
Asian, East Asian, Pacific Islander, or Indigenous Australian)
• No diabetes in first degree relative
• No history of abnormal glucose tolerance
• Normal pre-pregnancy weight and pregnancy weight gaincriteria and the National Diabetes Data Group (NDDG)
criteria. The Carpenter-Coustan criteria derive from
the work of O’Sullivan and Mahan [4], which Carpenter
and Coustan modified in 1982 [12]. In this method,
diagnosis of GDM is based on exceeding two or more
of the following threshold values:
 Fasting serum glucose concentration of 95 mg/dl
(5.3 mmol/l)
 1-h serum glucose concentration of 180 mg/dl
(10.0 mmol/l)
 2-h serum glucose concentration of 155 mg/dl
(8.6 mmol/l)
 3-h serum glucose concentration of 140 mg/dl
(7.8 mmol/l)
The NDDG criteria, meanwhile, are slightly less inclusive
than the Carpenter-Coustan criteria [13]. Furthermore, the
NDDG criteria were found to be less sensitive in diagnosing
GDM and in predicting incidence of perinatal morbidities
[14]. The NDDG criteria are also based on exceeding two
or more of the threshold values, which are as follows:
 Fasting serum glucose concentration of 105 mg/dl
 1-h serum glucose concentration of 190 mg/dl
 2-h serum glucose concentration of 165 mg/dl
 3-h serum glucose concentration of 145 mg/dl
Alternatively, the American Diabetes (ADA) criteria
for GDM diagnosis rely on a 75-gm glucose load and
consider fasting serum glucose concentration, 1-h glu-
cose concentration, and 2-h glucose concentration [15].
The glucose threshold values are, respectively, 95 mg/dl
(5.3 mmol/l), 180 mg/dl (10.0 mmol/l), and 155 mg/dl
(8.6 mmol/l). Again, two or more abnormal values are
required for diagnosis. Although these major criteria all re-
quire two or more abnormal values for diagnosis, studies
have shown that a single abnormal value is significantly
associated with increased risk of perinatal morbidities [16].
The World Health Organization (WHO) recommends
using a 75-gm glucose tolerance test for screening and
diagnosis. The threshold values are a fasting glucose
concentration of more than 126 mg/dl (7.0 mmol/l)
and/or a 2-h glucose concentration of more than
140 mg/dl (7.8 mmol/l) [17]. When the WHO criteria
are used, approximately twice as many patients will be
diagnosed with GDM compared to other criteria. How-
ever, there is no proven additional clinical benefit with
the use of WHO criteria [18]. The criteria for diagnosis
of GDM are summarized in Table 2.
Treatment
Evidence shows that screening for and treating GDM
lead to the reduction of perinatal morbidity and the
Table 2 Diagnostic criteria for gestation diabetes mellitus with their respective glucose values
Diagnostic criteria Fasting (mg/dl [mmol/l]) 1-h (mg/dl [mmol/l]) 2-h (mg/dl [mmol/l]) 3-h (mg/dl [mmol/l])
100-gm OGTT Carpenter/Coustan (two or
more abnormal)
95 (5.3) 180 (10.0) 155 (8.6) 140 (7.8)
100-gm OGTT NDDG (two or more abnormal) 105 (5.8) 190 (10.6) 165 (9.2) 145 (8.1)
75-gm OGTT WHO (one or more abnormal) 92-125 (5.1-6.9) ≥180 (10.0) 153-199 (8.5-11.0) -
75-gm OGTT ADA 95 (5.3) 180 (10.0) 155 (8.6) -
OGTT = Oral glucose tolerance test, NDDG = National Diabetes Data Group, WHO =World Health Organization 2013, ADA = American Diabetes Association
Mpondo et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:42 Page 3 of 7improvement of post-delivery outcomes [19]. As in other
types of diabetes, the cornerstone of GDM management
is glycaemic control [1]. Glycaemic control has been
shown to reduce adverse outcomes in pregnant women
with GDM [20, 21].
Target glucose values
Experts recommend that women with GDM should
maintain the following capillary blood glucose values: pre-
prandial glucose <95 mg/dl (5.3 mmol/l), 1-h postprandial
glucose <140 mg/dl (7.8 mmol/l), and 2-h postprandial
glucose <120 mg/dl (6.7 mmol/l) [1]. The American Col-
lege of Obstetrics and Gynaecology (ACOG) has similar
guidelines, the only exception being that both 130 mg/dl
and 140 mg/dl 1-h postprandial glucose values are con-
sidered acceptable [22]. Other recommendations sug-
gest maintaining fasting glucose levels of <90–99 mg/dl
(5.0–5.5 mmol/l), 1-h postprandial glucose levels of
<140 mg/dl (7.8 mmol/l), and 2-h postprandial glucose
levels of <120–127 mg/dl (6.7–7.1 mmol/l) [23].
Even if it is not possible to achieve the recommended
levels of glycaemic control, any improvement can be
beneficial given that perinatal complications are linked
to increasing serum glucose values [21, 24]. Despite the
benefits of glycaemic control, however, studies have
shown that very low target glucose values (<87 mg/dl)
are associated with increased rates of intrauterine fetal
growth retardation [20].
Medical nutrition therapy (MNT)
The first line of management for women with gestational
diabetes mellitus is dietary modification, often called
medical nutrition therapy [25]. Evidences indicates that
nutrition therapy is effective in reducing pregnancy and
perinatal complications and also in attaining glycaemic
control [25].
According to ADA recommendations, carbohydrate
intake should be approximately 40 % of total calorie intake
and should be selected from foods with low glycaemic
index values [26]. In pregnant women of normal body
weight (BMI between 18.5–24.9), the recommendation is
to consume 30–32 kcal/kg body weight, especially during
the second half of pregnancy [27]. However, those who are
overweight (BMI of 25 to 29.9) should ingest approximately25 kcal/kg body weight [28]. Other guidelines recommend
caloric intake based on BMI as follows: 30 kcal/kg for
a BMI of 22–25, 24 kcal/kg for a BMI of 26–29, and
12–15 kcal/kg for a BMI of >30.
75–80 % of women with GDM become euglycaemic
by following these caloric distribution guidelines. Asses-
sing fasting ketonuria provides a method of confirming a
woman’s caloric restriction, because caloric restriction of
at least 50 % has been associated with ketogenesis [29].
On the other hand, moderate caloric restriction of about
33 % has been associated with controlled glucose levels
without elevation of free fatty acids and ketonaemia
[28, 29]. Caloric restriction should be approached cau-
tiously, because studies show that elevated maternal
ketone levels are associated with impaired psychomotor
development [30].
Compared to diet alone, exercise with dietary modifi-
cations has been found to lead to improved glycaemic
control in one study [31]. The proposed mechanism for
such an improvement in glycaemic control is heightened
sensitivity of peripheral tissues to insulin. A supervised
home-based cycling program was helpful in maintaining
normal postprandial glucose levels in pregnant women
with diet-controlled GDM [32]. That said, another trial
using a partially home-based exercise program found no
reduction in blood glucose level [33]. This cohort did
demonstrate improved cardiovascular fitness, however.
Based on the available evidence on the benefits of ex-
ercise in managing GDM, ADA recommends moderate
exercise programs for women without medical or obstet-
rical complications [15]. There are no specific guidelines,
however, on how to employ exercise regimes to achieve
glycaemic control. For the general population, experts
tend to recommend exercising 3 or more times a week
for about 30 min.
Pharmacotherapy
Pharmacological intervention in the management of
GDM is usually employed when women fail to meet
established goals with conventional therapy of diet and
exercise. It is also indicated when elevated fasting glucose
levels occur while on conventional therapy, because diet-
ary modification has limited effect on these levels. Al-
though most women achieve adequate glycaemic control
Mpondo et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:42 Page 4 of 7with conventional therapy, 30–40 % do require the
addition of pharmacologic therapy at some point during
their pregnancies [34]. The pharmacological options in
this case include insulin or oral hypoglycaemic agents
(metformin and glyburide) [35, 36].Insulin
Insulin therapy is the most commonly used pharmaco-
therapy once MNT fails to achieve desired outcomes.
Insulin regimens often include intermediate-acting insulins
such as isophane and short-acting agents such as regular
recombinant insulin (Humulin R). Pharmacotherapy can
also involve the insulin analogues aspart and lisipro. Insulin
therapy decreases the frequency of fetal macrosomia and
the risk of perinatal morbidity [37]. Positive history of dia-
betes mellitus in a first-degree relative and multiple abnor-
mal values in the OGTT were strongly found to predict the
need for insulin management in women with GDM [38].
Studies have shown that insulin analogs (lispro and
aspart) are more effective than regular human insulin in
achieving targeted glucose values and minimizing the
risk for macrosomia [39, 40]. There is limited data on
the use of long-acting insulins in pregnancy. For women
with GDM who require insulin, isophane is therefore the
intermediate-acting insulin of choice [23]. Insulin ana-
logues lispro and aspart have been widely studied and
found to be clinically effective with minimal transfer
across the placenta; these agents have similar safety profiles
to human insulin [39]. Because the insulin analogues have
shorter durations of action and more rapid onsets of action
than regular insulin, they are associated with improved
postprandial glycaemic control and less postprandial
hypoglycaemia [41]. Glucose values that necessitate ini-
tiation of insulin are summarized in Table 3.
Oral hypoglycaemics
Oral hypoglycaemic agents used in the management of
GDM should be both effective and safe for the woman
and developing fetus. With the exception of glyburide and
metformin, oral hypoglycaemic drugs are generally not rec-
ommended due to concerns about potential teratogenicity
or prolonged neonatal hypogylcaemia from drug transport
across the placenta [42].
Glyburide
Glyburide, one of the two oral hypoglycaemic drugs used
for the management of GDM, acts primarily to enhanceTable 3 Glucose level cut-off points requiring insulin initiation in ge
Guideline Fasting (mg/dl [mmol/l]) 1-h postpr
ACOG(22) >95 (5.3) >130-140
ADA(15) >90-99 (5.0-5.5) >140 (7.8)
ACOG = American College of Obstetrics and Gynecology, ADA = American Diabetesinsulin secretion by the pancreas. It can be used as an al-
ternative for women who are unable or unwilling to take
insulin or, in some cases, as a first-line pharmacological
therapy. Studies have shown that glyburide, unlike other
sulphonylureas, does not cross the placenta in vivo or
in vitro [43, 44].
Studies examining the use of glyburide and insulin
for the management of GDM have found comparative
maternal and neonatal outcomes [45, 46]. Regarding
glyburide therapy, certain factors are associated with
higher rates of success, including initiation after 30 weeks
gestation or fasting blood glucose levels <110 mg/dl and
1-h postprandial glucose levels <140 mg/dl [47]. Despite
several studies supporting the efficacy and safety of glybur-
ide for women with GDM, ACOG and ADA guidelines do
not recommend its use until larger randomized controlled
trials are completed on the subject [15, 22]. However, a
survey conducted by ACOG found that up to 13 % of
American fellows prescribe glyburide as a first-line
pharmacological agent in women with GDM [48].
Metformin
Metformin is another oral hypoglycaemic agent considered
a potential substitute for insulin in GDM management. In a
randomized controlled trial involving women with GDM,
the use of metformin, whether alone or with supplemental
insulin, was not associated with increased perinatal compli-
cations compared to insulin alone [49]. Meanwhile, a 2013
meta-analysis found that metformin is comparable to insu-
lin regarding glycaemic control and neonatal outcomes
[50]. In another recent study, metformin use was associated
with similar desirable outcomes when compared to MNT
and insulin use; its use was not associated with a higher risk
of maternal or neonatal complications [51].
Glucose monitoring
In patients requiring insulin, the ideal frequency for glu-
cose monitoring has not been established. In common
practice, the patient generally checks glucose levels four
times a day [23]: once upon waking in the morning, before
meals, before bed and one or two hours postprandially to
ensure adequate glycaemic control. Postprandial glucose
levels are preferable to fasting glucose levels, because they
are more strongly associated with macrosomia [52]. Insu-
lin dose adjustments based on postprandial glucose levels
rather than preprandial levels were shown to be associated
with improvement in glycaemic control and reduction of
both maternal and fetal adverse outcomes [53].station diabetes mellitus
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Sliding Scale Insulin (SSI) is recommended to maintain
tight gycaemic control and avoid gycaemic events (i.e.
hypoglycaemia and hyperglycaemia) [54]. The sliding
scale insulin regimen consists of short acting insulin 4 to
6 times a day based on regularly obtained capillary blood
glucose measurements. However, studies have noted that
use of SSI regimen is not improving glucose control in
hospitalized patient [55-58]. In addition there is no
standard SSI regimen and dosage vary widely between
patients, providers and institutions [59].
For women with diet-controlled GDM, there are no
clinical guidelines or controlled trials addressing the
issue of monitoring frequency. In this case, the general
practice involves checking levels four times per day at
least two days per week [23]; when two values exceed
the limits over the course of a week, pharmacotherapy is
recommended.
Urine glucose monitoring is not useful in patients with
GDM. However, urine ketone monitoring can be used in
patients who are restricting calories to detect insufficient
caloric or carbohydrate intake [15].
Intrapartum management
During labor, women on pharmacological therapy re-
quire hourly evaluations of their glucose values, while
those with diet-controlled GDM do not require active
glucose management. Patients on insulin usually have
normal levels of glucose at the time of labor and also do
not need active management [23].
Delivery
There is no definitive data on the timing and mode of
delivery for pregnant women with GDM. If the patient
has normal or near normal glucose values, it is recom-
mended that she should deliver at term. The general
recommendation is that pregnancies complicated by
GDM should not extend beyond term. Elective cesarean
section has not been associated with significant reduction
of birth trauma and has not been found to be cost effective
[60]. Earlier delivery was associated with reduction of
macrosomia but not with reduction of other neonatal
complications [61].
Postpartum management
After delivery, insulin resistance usually resolves quickly,
as does the need for pharmacological management.
However, approximately 40–60 % of affected women will
develop type 2 DM later in life. They are also at an in-
creased risk of recurrent GDM that presents earlier in
future pregnancies. In these women, regular screening
for type 2 DM is strongly encouraged, beginning at
6 weeks post-delivery and annually thereafter. An OGTTshould be performed postpartum, 1 year post-delivery,
and every 3 years thereafter [23].
Conclusion
Despite GDM being one of the most common conditions
during pregnancy, the lack of data from well-designed stud-
ies leaves some uncertainty surrounding the need for
screening and management of this condition. Because the
condition is associated with both maternal and fetal com-
plications, screening and managing women at appropriate
gestational age is important to minimize adverse outcomes.
Glycaemic control can safely be achieved with a combin-
ation of nutritional and pharmaceutical interventions. Met-
formin and Glyburide have been shown to be as effective as
insulin in management of GDM. Effective communication
between physician, patient and primary care provider is
essential, as patients experience increased rates of GDM in
subsequent pregnancies and a higher lifetime risk of devel-
oping non-gestational diabetes. Further studies are required
to clarify the remaining controversies surrounding diagno-
sis and nuanced management practices.
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